Thrixen

Executive Summary

Thrixen is a Singapore-based diagnostics startup founded in 2021, developing proprietary engineered protein binders and a novel assay format for rapid, point-of-care biomarker detection. Leveraging expertise from the Singapore-MIT Alliance, the company aims to deliver affordable, scalable diagnostic tests for infectious diseases and other health conditions. Its technology platform offers the potential for high sensitivity and specificity at a low cost, addressing critical gaps in decentralized testing in resource-limited settings. Thrixen has assembled a team of experienced scientists and advisors, and is advancing multiple prototype assays toward clinical validation. The global point-of-care diagnostics market is projected to exceed $50 billion by 2028, driven by demand for rapid, accurate testing in infectious disease management. Thrixen’s initial focus on infectious diseases leverages immediate clinical needs, with potential to expand into chronic diseases and oncology. The company has completed early feasibility studies demonstrating proof-of-concept for its binder technology and is now scaling manufacturing and preparing for clinical trials. Strategic partnerships with local healthcare providers and distributors are being explored to support market entry in Southeast Asia. With a lean team and capital-efficient approach, Thrixen is positioned to capture a share of the growing POC diagnostics market, though regulatory clearance and commercial traction remain key milestones ahead.

Upcoming Catalysts (preview)

• Q2 2027Completion of first clinical validation study for lead infectious disease assay70% success
• Q4 2026Strategic manufacturing or distribution partnership in Southeast Asia60% success
• Q1 2028Regulatory submission for CE marking or Singapore HSA approval50% success